

The MOXle Study

A study of omaveloxolone (RTA 408) in Friedreich's ataxia

MOXle is a double blind, placebo-controlled, multi-center Phase 2 study of the safety and efficacy of omaveloxolone (RTA 408) in Friedreich's ataxia

About the Study

Treatment: Omaveloxolone or placebo capsules taken by mouth once daily

Approximately 8 visits over 16 weeks

Primary endpoint: Change in peak workload, measured on a recumbent bicycle

Cost of travel may be reimbursed

Criteria for Participation

Between ages 16 and 40

Genetically confirmed Friedreich's ataxia

Willing to discontinue taking some medications

Not pregnant, planning a pregnancy, or breastfeeding

Recruiting Study Center Locations

United States



 Los Angeles, California: UCLA
Susan Perlman, MD

 Gainesville, Florida: University of Florida
S.H. Subramony, MD

 Tampa, Florida: University of South Florida
Theresa Zesiewicz, MD

 Atlanta, Georgia: Emory University Hospital
George Wilmot, MD

Europe



 Columbus, Ohio: Ohio State University
Chad Hoyle, MD

 Philadelphia, Pennsylvania: CHOP
David Lynch, MD

 Innsbruck, Austria: Medical University Innsbruck
Sylvia Boesch, MD

 Parkville, Victoria, Australia: Murdoch Children's Research Institute
Martin Delatycki, MD

Australia



Contact information for participating study centers can be found on the clinicaltrials.gov listing